Previous studies showed the efficacy of a BCL(X)L selective inhibitor in combination with genotoxic chemotherapy to induce cell death in solid tumors such as osteosarcoma, ovarian, colon, and breast cancer32–35. Here, BCL2L1 is linked to osteosarcoma.